BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

...fat accumulation. Pfizer Inc. markets Azulfidine for inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Promentis Pharmaceuticals Inc....
BioCentury | Sep 25, 2017
Financial News

Venture roundup: Fusion, IsoPlexis, Tempus

...clinical database with an analytical machine-learning platform to personalize and improve cancer care. Jennie Walters FPX-01 SXC-2023 Fusion Pharmaceuticals Inc. Promentis Pharmaceuticals Inc. IsoPlexis...
BioCentury | Mar 31, 2017
Financial News

Promentis completes venture financing

...Neurology company Promentis Pharmaceuticals Inc. (Milwaukee, Wisc.) raised $26 million in a series C round led by new...
...Black Pearl, the Golden Angel Network and individual investors also participated. Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Alicia Parker Promentis Pharmaceuticals Inc....
BioCentury | Mar 30, 2017
Financial News

Promentis raises $26M in series C

...OrbiMed's Stephen Squinto joined Promentis' board, as did F-Prime's Tom Beck and Aisling's Stacey Seltzer. Becky Simon Promentis Pharmaceuticals Inc. Solute...
BioCentury | Jan 27, 2014
Financial News

Promentis Pharmaceuticals completes venture financing

Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Business: Neurology Date completed: 1/21/14 Type: Venture financing Raised: $2.9 million Investors: Black Horse Investments; Golden Angel Investors; private investors WIR Staff Neurology...
BioCentury | Aug 5, 2013
Company News

Promentis Pharmaceuticals management update

Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Business: Neurology Hired: Chad Beyer as president and CEO WIR Staff...
Items per page:
1 - 6 of 6
BioCentury | Sep 18, 2019
Distillery Therapeutics

SLC7A11 and mGluR5 identified as targets for hepatic alcoholic steatosis

...fat accumulation. Pfizer Inc. markets Azulfidine for inflammatory bowel disease (IBD) and rheumatoid arthritis (RA). Promentis Pharmaceuticals Inc....
BioCentury | Sep 25, 2017
Financial News

Venture roundup: Fusion, IsoPlexis, Tempus

...clinical database with an analytical machine-learning platform to personalize and improve cancer care. Jennie Walters FPX-01 SXC-2023 Fusion Pharmaceuticals Inc. Promentis Pharmaceuticals Inc. IsoPlexis...
BioCentury | Mar 31, 2017
Financial News

Promentis completes venture financing

...Neurology company Promentis Pharmaceuticals Inc. (Milwaukee, Wisc.) raised $26 million in a series C round led by new...
...Black Pearl, the Golden Angel Network and individual investors also participated. Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Alicia Parker Promentis Pharmaceuticals Inc....
BioCentury | Mar 30, 2017
Financial News

Promentis raises $26M in series C

...OrbiMed's Stephen Squinto joined Promentis' board, as did F-Prime's Tom Beck and Aisling's Stacey Seltzer. Becky Simon Promentis Pharmaceuticals Inc. Solute...
BioCentury | Jan 27, 2014
Financial News

Promentis Pharmaceuticals completes venture financing

Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Business: Neurology Date completed: 1/21/14 Type: Venture financing Raised: $2.9 million Investors: Black Horse Investments; Golden Angel Investors; private investors WIR Staff Neurology...
BioCentury | Aug 5, 2013
Company News

Promentis Pharmaceuticals management update

Promentis Pharmaceuticals Inc. , Milwaukee, Wis. Business: Neurology Hired: Chad Beyer as president and CEO WIR Staff...
Items per page:
1 - 6 of 6